Penserra Capital Management’s AstraZeneca AZN Stock Holding History

Penserra Capital Management’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$198K	Buy	1,049 +69	+7%	+$13K	﹤0.01%	703
2026 Q1	$193K	Buy	+980	New	+$189K	﹤0.01%	676
2025 Q4	–	Sell	-923	Closed	-$141K	–	1062
2025 Q3	$141K	Sell	923 -44	-5%	-$6.66K	﹤0.01%	734
2025 Q2	$135K	Sell	967 -625	-39%	-$87.6K	﹤0.01%	696
2025 Q1	$233K	Buy	1,592 +113	+8%	+$16.3K	﹤0.01%	715
2024 Q4	$193K	Sell	1,479 -84	-5%	-$11.8K	﹤0.01%	752
2024 Q3	$243K	Sell	1,563 -13,859	-90%	-$2.24M	0.01%	678
2024 Q2	$2.41M	Buy	15,422 +11,332	+277%	+$1.71M	0.03%	332
2024 Q1	$554K	Sell	4,090 -1,884	-32%	-$249K	0.01%	562
2023 Q4	$804K	Buy	5,974 +924	+18%	+$120K	0.02%	414
2023 Q3	$683K	Buy	5,050 +2,480	+96%	+$339K	0.01%	430
2023 Q2	$367K	Buy	2,570 +755	+42%	+$111K	0.01%	624
2023 Q1	$251K	Sell	1,815 -19,648	-92%	-$2.64M	0.01%	644
2022 Q4	$2.91M	Buy	21,463 +21,148	+6,714%	+$2.65M	0.06%	296
2022 Q3	$34K	Sell	315 -8,634	-96%	-$1.1M	﹤0.01%	855
2022 Q2	$1.18M	Buy	+8,949	New	+$1.17M	0.03%	370

Other funds holding AZN

Evelyn Partners London $46.9B AUM

Investor AB Stockholm, Sweden $14.4B AUM 4.07% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Penserra Capital Management's AZN Position: Q2 2026 in Review

Penserra Capital Management increased its AstraZeneca (AZN) stake by 7% in Q2 2026, buying an estimated $13K and bringing the position to 1,049 shares worth $198K. The position accounts for ﹤0.01% of the portfolio, ranked #703.

Penserra Capital Management first reported a position in AZN in Q2 2022 and has held it in 16 quarters since. The position peaked at $2.91M in Q4 2022. 1,495 funds tracked by Wall St. Rank hold AZN as of Q2 2026.

Penserra Capital Management held 1,049 shares of AstraZeneca worth $198K as of Q2 2026.
Penserra Capital Management bought 69 AstraZeneca shares in Q2 2026, an estimated $13K.
AstraZeneca made up ﹤0.01% of Penserra Capital Management's portfolio in Q2 2026, its #703 holding.
Penserra Capital Management first reported a position in AstraZeneca in Q2 2022 and has held it in 16 quarters since.
Penserra Capital Management's AstraZeneca position peaked at $2.91M in Q4 2022.
1,495 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2026.

Based on Penserra Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.